OxiProteomics is a CRO French specialized in biomarker assessment providing research services for skin care dermo-cosmetics, medical devices, and dermatology efficacy evaluation. Spined-out from Sorbonne University in 2014, their uniqueness is a specific know-how on non-targeted & targeted proteomics approaches adapted to skin and hair evaluation.

OxiProteomics supports their clients on molecular target identification, target validation, efficacy testing, mechanistic studies, prediction of responders, and biomarkers discovery. They also propose predictive pre-clinical skin models coupled with spatial proteomics analyses, based on the organ culture of human skin samples.

OxiProteomics ables work with clinical samples to perform bio-analysis. They also mechanistic investigator-initiator trials with the analysis of biopsies and non-invasive samples.

In the complex world of biomanufacturing, technical precision is the standard, but human commitment is the difference. LFB Biomanufacturing understands that a biological breakthrough is more than a formula or a process : it is a promise waiting to be kept.

LFB Biomanufacturing sees itself as the human link between your science and patient’s story.
They know that moving a molecule from the lab to the real world requires more than just high-end equipment. It requires dedicated expertise that turns biological breakthroughs into a patient’s reality.

When you partner with them, you are not just accessing a facility; you are connecting with a team that takes ownership of your vision. LFB Biomanufacturing is the bridge that ensures your innovation doesn’t just stay in a vial, but becomes the next chapter in a person’s life.
LFB Biomanufacturing: The human link between your science and their story.

Roowin is a privately owned and agile Contract Research Organisation (CRO), headquartered in Riom (Clermont-Ferrand), France. Specializing in complex chemistry, we provide a comprehensive suite of chemical and analytical services designed to accelerate your drug development journey.

From early drug discovery through process development, we partner with you to advance your small molecule candidates—supporting you all the way to IND/IMPD submission and beyond, including Phase II API licensing or small-scale commercial production (up to ~20 kg).”

With almost 30 thirty years of experience, more than a hundred molecules advanced to the clinic, and a track record of producing the first batches for dozens of startups —some now valued at several billion on the stock market—Roowin demonstrates an exceptionally strong proven record.

Within its custom manufacturing department, Roowin studies all projects of API synthesis under cGMP (current Good Manufacturing Practices).
Roowin can produce batches in a wide range of quantities (from 50 mg up to several dozen kilograms) and support the development of APls from the exploratory stage to advanced clinical phases.

Throughout a cGMP project, Roowin provides complete production-related documentation, satisfying the highest industry standards.
From identification and purchase of raw material, through detailed intermediate analysis and up to final batch release, Roowin minutely tracks every step on the way to the final API.

Firalis Molecular Precision (FMP) is a CAP-accredited, GCLP-compliant multi-omics Contract Research Organization (CRO) delivering high-quality bioanalytical services to pharmaceutical, biotechnology, and academic partners worldwide. With over 15 years of experience and 100+ clients globally, FMP operates at the intersection of precision medicine and translational research, supporting drug discovery, clinical development, and companion diagnostics programs across oncology, neurology, immunology, rare diseases, and cardiovascular disease.

What sets FMP apart is its ability to go beyond data generation. By integrating multimodal molecular data, spanning genomics (NGS, whole exome sequencing, RNA sequencing, DNA methylation sequencing), proteomics (Olink®-certified, immunoassays), and transcriptomics, with clinical context, FMP transforms complex biological information into actionable insights that directly inform drug target discovery, biomarker R&D, mechanism of action studies, target engagement, and clinical trial testing.

FMP’s GCLP-compliant and CAP-accredited infrastructure ensures the regulatory rigor required for biomarker data submitted in support of IND and NDA filings. Its scientific team combines deep omics expertise with a client-first project management approach, providing end-to-end support from study design and sample logistics to data analysis and biomarker interpretation. With a commitment to turnaround excellence, data traceability, and methodological innovation, Firalis Molecular Precision serves as a strategic scientific partner for organizations seeking to accelerate their pipelines and de-risk their clinical programs through molecular precision.

Not just an ophthalmology-focused CRO, Iris Pharma helps clients around the world navigate every stage of the drug and device development process and delivers customized solutions for:

– Assessing possible therapeutic effect in ocular diseases

– Adding value to promising drug candidates or medical devices

– Designing development plans and preclinical packages and carrying out studies to proceed.

They accompany start-up companies, biotechnology companies, large pharmaceutical companies, pharmaceutical labs, universities, research organizations and consultants in their ophthalmology projects.

Iris Pharma’s a la carte services include:

***PRECLINICAL DEVELOPMENT SERVICES*** – Animal efficacy models & in vivo pharmacology studies – GLP regulatory studies (ocular PK, safety and tolerability) – Proof of concept & pilot studies

***INNOVATIVE TECHNOLOGY PLATFORM & TECHNIQUES*** – Bioanalytical testing services – Cellular and molecular biology assays – Non-GMP, non-GLP, early preclinical ocular formulation – Ocular histology

Their assets: – All ophthalmic indications mastered – 70 FDA, PMDA & EMA new ocular drug approvals and ophthalmic medical device marketing authorizations – State-of-the-art medical and scientific equipment – Highly specialized and qualified staff – CIR agreement

Eurofins Optimed is a French Contract Research Organization (CRO) and Clinical Pharmacology Unit specialized in early‑phase clinical development. With more than 35 years of experience, the company supports pharmaceutical, biotechnology and medical device developers in the design, execution and management of Phase I and Phase II clinical trials in healthy volunteers and patients. Operating from its dedicated clinical facility in Gières, France, Eurofins Optimed combines scientific rigor, regulatory expertise and operational excellence to accelerate the transition from preclinical research to clinical proof of concept.

This established expertise now benefits from the French Fast Track regulatory framework, enabling accelerated timelines with authorization potentially granted within 14 days in eligible cases, further enhancing the attractiveness of France. Close interactions with sponsors, investigators and regulatory authorities further contribute to efficient study initiation and execution within this robust regulatory environment.

Eurofins Optimed provides a full‑service CRO offering, covering study design, regulatory submissions, clinical operations, volunteer and patient recruitment, pharmacovigilance, data management and biometry. The organization is particularly recognized for its expertise in First‑in‑Human studies, bioequivalence, drug–drug interaction studies, food‑effect studies and QT assessment, ensuring robust and high‑quality data generation in compliance with GCP and international regulatory standards.

A key differentiator of Eurofins Optimed is its strong integration within the Eurofins Group, enabling seamless collaboration with Eurofins ADME Bioanalyses and other specialized entities. This integrated model provides sponsors with end‑to‑end solutions combining clinical research, bioanalysis, pharmacokinetics and biomarker expertise, particularly valuable for complex and innovative drug development programs. Through this comprehensive and coordinated approach, Eurofins Optimed acts as a strategic partner for companies seeking to de‑risk and optimize early clinical development.

ETAP-LAB is an independent preclinical CRO that provides efficacy testing and pharmacology services to pharmaceutical, biotechnology and medtech companies.

ETAP-LAB has 35+ years of expertise with 4 services:
– BrainXplore: in vitro and in vivo models of Alzheimer, Parkinson, ALS, depression and anxiety.
– Stro@lliance: more than 10 models of both ischemic and hemorrhagic stroke.
– SkinAxis: inflammation models (psoriasis, atopic dermatitis,…) and wound healing (different shape, size, depth; skin grafting).
– SynCROsome: dedicated to Cardiology including HFpEF, HFrEF, Pulmonary Artery hypertension, Systemic hypertension, thrombosis.

ETAP-LAB’s services are designed to support drug discovery phases ranging from in vitro lead optimization to non-GLP animal testing (POC, PK/PD, non-regulatory safety pharmacology), to evaluate your drug candidates (small molecules, antibodies, cell therapies…) and medical devices.

ETAP LAB’s services rely on state of the art facilities and equipment, including high content imaging, in vivo imaging platforms (MRI, PET scan, echocardiography, dermoscopy), microsurgery capabilities, and comprehensive immunohistochemistry and bioassay readouts.

Neuron Experts is a private Contract Research Organization (CRO) established in 2008, specializing in neuronal culture systems modeling neurodegenerative diseases. The company has developed a range of proprietary assays based on human and rat in vitro models reproducing key pathological features of Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), multiple sclerosis (MS), and frontotemporal dementia (FTD). These models are used to evaluate compound efficacy and to investigate mechanisms of action.

Since 2025, Neuron Experts has collaborated with two French CROs—Motac, focused on in vivo studies, and Cynbiose, specialized in bioavailability and regulatory toxicology—within the INSPiRE consortium, with the objective of providing comprehensive preclinical development services for biotechnology companies.

In 2014, the company established a neurodermatology department dedicated to studying interactions between sensory neurons and the skin. It has developed human in vitro models to assess compound activity in dermatological and cosmetic applications. Notably, Neuron Experts has developed a reconstructed human epidermis model innervated with sensory neurons, enabling the evaluation of the effects of topically applied compounds on neuronal activity.

CYTOO transforms drug discovery through advanced micropatterned platforms that deliver highly physiological cell models, generating structural, functional, and metabolic readouts while enhancing AI-driven image analysis.

Within a portfolio of clinically relevant models, CYTOO’s flagship MyoScreen™ platform addresses inherited and acquired muscle disorders. Emerging models target obesity-related metabolic dysfunction, including myosteatosis and insulin resistance.

From high-throughput screening to GMP-grade potency assays, CYTOO has supported 60+ drug development programs, advancing therapies via standardized services, custom development, and strategic partnerships.

The company has a very strong expertise in neuro-muscular diseases, also other genetic disorders and metabolic disorders (muscle weakness and waste, obesity, diabetes).

The mission of CYTOO is to help advancing therapeutic candidates to the clinics leveraging its unique technology platform, from target identification, primary and secondary drug screening, up to the development of GMP-compliant potency assays for batch release.

Examples of targeted diseases:
Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1, DM2), Facioscapulohumeral Muscular Dystrophy (FSHD), Glycogen Storage Diseases (Pompe Disease), Mitochondrial Disorders (PMM – Primary Mitochondrial Myopathies), Metabolic Disorders (Sarcopenia, Diabetes, Obesity…)

Many programs begin with strong biological findings but struggle to translate early hits, fragments, or tool compounds into viable lead candidates. This is often due to limited medicinal chemistry resources and insufficient insight into the challenges of advancing a lead toward a drug candidate and generating the data required to secure seed funding.

Oxeltis address this by:
• Seamless integration of in silico design (CADD, SBDD, LBDD, AI/ML) with high-quality synthesis, in partnership with Molecular Forecaster (Montreal) and Assay development/in vitro biological screening in partnership with Partex.AI.Labs
• Rapid hit-to-lead and lead optimization, with a track record of delivering high-quality compounds efficiently and a highly skill team of chemists (50% Ph.D., 50% M.Sc.)
• Expertise in complex and enabling chemistries, supported by our hybrid SFC platform for rapid purification and scale-up (up to 25g/day) of chiral/achiral mixtures.
• Comprehensive biological services, including assay design, in vitro screening, and early pharmacology profiling, integrated with chemistry to accelerate DMTA cycles and decision-making.